PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q2 2014 13F Holders as of 30 Jun 2014

Type / Class
Equity / COM
Total 13F shares
50,851,748
Share change
-1,453,485
Total reported value
$219,162,625
Put/Call ratio
112%
Price per share
$4.31
Number of holders
73
Value change
-$5,776,419
Number of buys
32
Number of sells
45

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q2 2014

As of 30 Jun 2014, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 73 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 50,851,748 shares. The largest 10 holders included FEDERATED INVESTORS INC /PA/, Broadfin Capital, LLC, BAKER BROS. ADVISORS LP, FMR LLC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., TUDOR INVESTMENT CORP ET AL, VANGUARD GROUP INC, HIGHLAND CAPITAL MANAGEMENT LP, and WELLINGTON MANAGEMENT CO LLP. This page lists 73 institutional shareholders reporting positions in this security for the Q2 2014 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.